Autophagy

Autophagy is an intracellular catabolic mechanism. In certain stressful situations, lysosomes degrade degenerated, damaged, aged or non-functional cells, organelles and biomolecules such as proteins and nucleic acids to achieve cellular protection and organelles from cell damage. Autophagy is achieved by forming a bilayer membrane structure in the cytoplasm that wraps the material to be removed and transports it to the lysosome for degradation. In multicellular organisms, newly formed autophagic vesicles form autophagic endosomes by fusing with vesicles in different stages of the endocytic lysosomal pathway, such as early endosomes and late endosomes, before fusing with lysosomes, a process known as autophagic vesicle maturation. Abnormalities in autophagosome maturation, which is precisely regulated by cellular trophic state and stress signaling pathways, lead to the accumulation of large amounts of damaged organelles and toxic protein aggregates in cells.

Cat. No.	Product name
BP12878	trifarotene
BP12878	trifarotene is a potent and selective RARγ agonist with 65-fold and 16-fold selectivitiy for the RARγ (EC50=7.7 nM) over RARα (EC50=500 nM) and RARβ (EC50=125 nM).
BP12879	MSX-122
BP12879	MSX-122 is a novel small molecule and partial CXCR4 antagonist, with potent inhibition of CXCR4/CXCL12 actions(IC50 = 10 nM).
BP12880	Bicalutamide
BP12880	Bicalutamide, a synthetic, nonsteroidal antiandrogen, competitively binds to cytosolic androgen receptors in target tissues, thereby inhibiting the receptor binding of androgens.
BP12881	Heparin sodium salt
BP12881	Heparin sodium is a sulfated polysaccharide, which belongs to the family of glycosaminoglycans. It is utilized as an anticoagulant and interacted with diverse proteins for numerous important biological activities.Heparin sodium salt significantly inhibits exosome-cell interactions.
BP12882	Rabusertib
BP12882	Rabusertib is an inhibitor of the cell cycle checkpoint kinase 1 (chk1) with potential chemopotentiating activity. Rabusertib has been used in trials studying the treatment of Cancer, Solid Tumors, Advanced Cancer, Pancreatic Neoplasms, and Non-Small Cell Lung Cancer.
BP12883	Veliparib
BP12883	Veliparib (ABT-888) is an orally bioavailable inhibitor of PARP (Kis: 5.2/2.9 nM for PARP1/2). It enhances apoptosis and autophagy.
BP12884	Veliparib dihydrochloride
BP12884	Veliparib (ABT-888) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM in cell-free assays, respectively. It is inactive to SIRT2.
BP12885	BMS-582949 hydrochloride
BP12885	The BMS-582949 hydrochloride is a highly specific p38α MAPK inhibitor (IC50: 13 nM).
BP12886	Dactolisib
BP12886	Dactolisib is an orally bioavailable inhibitor of PI3K and mTOR (IC50s: 4 nM/5 nM/7 nM/75 nM, and 20.7 nM for p110α/p110γ/p110δ/p110β and mTOR).
BP12887	BGT226
BP12887	Bgt226 is a novel dual PI3K / mTOR inhibitor, it acts on PI3K α/β/γ with IC50 of 4 nM / 63 nM / 38 nM, respectively.
BP12888	Enzalutamide
BP12888	Enzalutamide (MDV 3100) is a non-steroidal androgen receptor (AR) antagonist (IC50: 36 nM in LNCaP prostate cells).
BP12889	SRT 1720
BP12889	SRT 1720 is a selective activator of human SIRT1 (EC1.5: 0.16 μM) and is >230-fold less potent for SIRT2 and SIRT3.
BP12890	PPQ-102
BP12890	PPQ-102, an effective CFTR inhibitor, can completely inhibit CFTR chloride current (IC50: 90 nM).
BP12891	BIX-01294
BP12891	BIX-01294 is an G9a Histone Methyltransferase inhibitor(IC50 : 1.9 μM).
BP12892	Oprozomib
BP12892	Oprozomib (ONX 0912), an inhibitor for CT-L activity of 20S proteasome β5（IC50=36 nM）/LMP7（IC50=82 nM）, is orally bioavailable. Oprozomib also has potential antineoplastic activity.
BP12893	Lumacaftor
BP12893	VX-809 is a CFTR modulator that corrects the folding and trafficking of CFTR protein. It enhances F508del-CFTR protein maturation in FRT cells (EC50: 100 nM).
BP12894	OSI-027
BP12894	OSI-027 is a selective and potent dual inhibitor of mTORC1 and mTORC2 with IC50 of 22 nM and 65 nM, and more than 100-fold selectivity observed for mTOR than PI3Kα, PI3Kβ, PI3Kγ or DNA-PK. Phase 1.
BP12895	GSK-690693
BP12895	GSK690693 is a pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 2 nM/13 nM/9 nM, also sensitive to the AGC kinase family: PKA, PrkX and PKC isozymes. Phase 1.
BP12896	FIPI
BP12896	FIPI is a derivative of halopemide which potently inhibits both PLD1 (IC50 = 25 nM) and PLD2 (IC50 = 20 nM); prevents PLD regulation of F-actin cytoskeleton reorganization, cell spreading, and chemotaxis.
BP12897	AZ304
BP12897	AZ304 is an ATP-competitive dual BRAF kinase inhibitor, potently inhibits BRAF (WT), BRAF (V600E), and wild type CRAF (IC50s: 79/38/68 nM).